“President Trump’s executive order to streamline regulatory processes for pharmaceutical manufacturing marks a strategic turning point in U.S. industrial policy. Puerto Rico, as a proven leader in this sector, is uniquely positioned to catalyze this vision and demonstrate how it can be rapidly translated into tangible Made in America production.

Puerto Rico is a proven asset. Our island is home to more than 50 FDA-approved pharmaceutical manufacturing facilities, produces 6 of the world’s top 10 biologics, and boasts a bioscience workforce of over 80,000 skilled professionals. With more than 70 years of experience in this sector, we are the most mature, reliable, and scalable component of the U.S. manufacturing ecosystem.

This federal policy does not just benefit Puerto Rico, it is empowered by it. With our existing infrastructure, we can rapidly scale up current operations, launch new production lines, and serve as an agile testing ground for models that can later be replicated in other jurisdictions. What we achieve here will be proof of concept for the nation.

Puerto Rico is reshore ready. At the Department of Economic Development and Commerce (DEDC), we have immediately activated our Reshoring Task Force, established under Executive Order 2025-012, to seize this opportunity. Our strategy is built on three pillars: (1) accelerating permitting through our One-Stop Investment Window, (2) expanding workforce training programs specifically for pharmaceutical manufacturing, and (3) enhancing competitive incentives under Act 60. We will also establish direct coordination channels with the federal agencies named in the executive order—FDA, EPA, and the U.S. Army Corps of Engineers—to ensure companies in Puerto Rico can swiftly benefit from the streamlined regulatory environment.

Manufacturing in Puerto Rico is manufacturing in the United States. Every medicine produced on our island reduces dependency on foreign supply chains, strengthens national security, and reinforces U.S. industrial resilience from a jurisdiction already operating at the highest regulatory and operational standards.

The recent reintroduction of the MMEDS Act by Representative Nicole Malliotakis—a bill that incentivizes manufacturing in economically distressed areas such as Puerto Rico—further amplifies this moment. Coupled with this executive action and the leadership of Governor González-Colón, we now have the ideal framework to attract new investment, generate high-quality jobs, and expand national production capacity.

Puerto Rico is reshore ready. At the Department of Economic Development and Commerce (DEDC), we have immediately activated our Reshoring Task Force, established under Executive Order 2025-012, to seize this opportunity. Our strategy is built on three pillars: (1) accelerating permitting through our One-Stop Investment Window, (2) expanding workforce training programs specifically for pharmaceutical manufacturing, and (3) enhancing competitive incentives under Act 60. We will also establish direct coordination channels with the federal agencies named in the executive order—FDA, EPA, and the U.S. Army Corps of Engineers—to ensure companies in Puerto Rico can swiftly benefit from the streamlined regulatory environment.

Manufacturing in Puerto Rico is manufacturing in the United States. Every medicine produced on our island reduces dependency on foreign supply chains, strengthens national security, and reinforces U.S. industrial resilience from a jurisdiction already operating at the highest regulatory and operational standards.

The recent reintroduction of the MMEDS Act by Representative Nicole Malliotakis—a bill that incentivizes manufacturing in economically distressed areas such as Puerto Rico—further amplifies this moment. Coupled with this executive action and the leadership of Governor González-Colón, we now have the ideal framework to attract new investment, generate high-quality jobs, and expand national production capacity.

Puerto Rico is ready to lead this historic chapter in America’s reindustrialization. We offer the fastest, most reliable, and fully compliant path to achieving a robust, secure, and globally competitive Made in America pharmaceutical manufacturing ecosystem with real impact for both the island and the nation.”

###